IRIS
PARISI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.825
AS - Asia 2.105
EU - Europa 1.249
SA - Sud America 466
Continente sconosciuto - Info sul continente non disponibili 251
AF - Africa 86
OC - Oceania 4
Totale 6.986
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.714
SG - Singapore 626
VN - Vietnam 497
IT - Italia 412
CN - Cina 396
BR - Brasile 349
RU - Federazione Russa 336
HK - Hong Kong 294
FR - Francia 127
DE - Germania 92
IN - India 65
BD - Bangladesh 57
GB - Regno Unito 56
FI - Finlandia 47
CA - Canada 46
NL - Olanda 44
MX - Messico 43
AR - Argentina 38
IE - Irlanda 36
IQ - Iraq 24
CI - Costa d'Avorio 22
AT - Austria 21
EC - Ecuador 21
ID - Indonesia 20
ZA - Sudafrica 20
CO - Colombia 17
ES - Italia 16
SE - Svezia 16
PK - Pakistan 15
JP - Giappone 14
VE - Venezuela 13
KR - Corea 12
PL - Polonia 11
SA - Arabia Saudita 10
MA - Marocco 9
TR - Turchia 9
AE - Emirati Arabi Uniti 8
CL - Cile 8
EG - Egitto 8
PH - Filippine 8
PY - Paraguay 8
PE - Perù 7
TW - Taiwan 7
UA - Ucraina 7
KE - Kenya 6
LT - Lituania 6
CR - Costa Rica 5
DZ - Algeria 5
TH - Thailandia 5
TN - Tunisia 5
UZ - Uzbekistan 5
AU - Australia 4
BG - Bulgaria 4
IL - Israele 4
KZ - Kazakistan 4
LB - Libano 4
PA - Panama 4
PR - Porto Rico 4
AZ - Azerbaigian 3
BY - Bielorussia 3
JO - Giordania 3
NG - Nigeria 3
NP - Nepal 3
UY - Uruguay 3
AL - Albania 2
BO - Bolivia 2
JM - Giamaica 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BS - Bahamas 1
CH - Svizzera 1
CY - Cipro 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
KG - Kirghizistan 1
KW - Kuwait 1
LY - Libia 1
MM - Myanmar 1
MU - Mauritius 1
MY - Malesia 1
MZ - Mozambico 1
NI - Nicaragua 1
OM - Oman 1
PT - Portogallo 1
RO - Romania 1
SC - Seychelles 1
SI - Slovenia 1
SN - Senegal 1
Totale 6.731
Salva come PNG Salva come JPEG
Città #
Ashburn 754
San Jose 369
Singapore 356
Council Bluffs 312
Hong Kong 286
Ho Chi Minh City 175
Dallas 173
Hanoi 109
Beijing 102
Boardman 100
Los Angeles 79
Lauterbourg 71
The Dalles 66
Hefei 61
Moscow 52
Santa Clara 45
Munich 44
Milan 42
Orem 37
Helsinki 36
Dublin 34
New York 34
São Paulo 33
Rome 30
Buffalo 29
Phoenix 27
Da Nang 24
Mexico City 24
Shenzhen 24
Abidjan 22
Chicago 22
Chennai 21
Nuremberg 19
Ancona 18
Montreal 18
Chandler 17
London 17
Fairfield 15
Houston 15
Shanghai 15
Haiphong 14
Seattle 12
Tokyo 12
Zhengzhou 12
Brasília 11
Camerino 11
Denver 11
Vienna 11
Amsterdam 10
Des Moines 10
Jacksonville 10
Miano 10
Turku 10
Warsaw 10
Washington 10
Bologna 9
Hải Dương 9
Manchester 9
Boston 8
Can Tho 8
Elk Grove Village 8
Frankfurt am Main 8
New Delhi 8
Rio de Janeiro 8
San Francisco 8
Toronto 8
Urbisaglia 8
Ann Arbor 7
Biên Hòa 7
Dhaka 7
Florence 7
Johannesburg 7
Lima 7
Miami 7
Naples 7
Ninh Bình 7
Stockholm 7
Atlanta 6
Baghdad 6
Bari 6
Bogotá 6
Brooklyn 6
Erbil 6
Guangzhou 6
Matelica 6
Medellín 6
Quito 6
Secaucus 6
Thái Bình 6
Asunción 5
Campinas 5
Cotia 5
Detroit 5
Goiânia 5
Guayaquil 5
Lawrence 5
Louisville 5
Mumbai 5
Nairobi 5
Porto Alegre 5
Totale 4.187
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 201
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 160
Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report 140
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status 135
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 134
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 124
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 123
Pemigatinib in pazienti affetti da colangiocarcinoma localmente avanzato o metastatico con fusione o riarrangiamento di FGFR2 pretrattati: analisi congiunta degli studi di coorte multicentrici, osservazionali, "real-world" francese PEMI-BIL e italiano PEMI-REAL 122
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 117
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 116
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis 113
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 113
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 112
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 109
Communication in oncology between healthcare providers, patients, the scientific community, and the media: recommendations from the Italian Association of Medical Oncology (AIOM) 108
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study 108
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 106
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 104
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 102
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 102
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers 101
Immunotherapy in Triple-Negative Breast Cancer 99
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 99
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic 95
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 94
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 93
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 90
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies 89
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study 89
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 89
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 85
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 85
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort 85
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study 83
Evaluation of prognostic factors for survival in transverse colon cancer 83
Multimodality treatment in metastatic gastric cancer: From past to next future 82
What is known about theragnostic strategies in colorectal cancer 82
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study 82
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer 81
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 80
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 79
Is it a new era for intrahepatic cholangiocarcinoma? 77
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 77
How to best exploit immunotherapeutics in advanced gastric cancer: Between biomarkers and novel cell-based approaches 77
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 77
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 76
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 76
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption 74
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 73
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 73
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 71
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 70
Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis 67
The emerging role of immunotherapy in the treatment of anal cancer 66
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 65
A case of segmental hepatic necrosis complicating oxaliplatin and capecitabine chemotherapy: A case report and review of the literature 65
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 63
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 62
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 62
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 60
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 60
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 60
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 59
Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study 59
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 59
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 59
SEX-RELATED DIFFERENCES IN EFFICACY AND SAFETY OF IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA: SYSTEMATIC REVIEW AND META-ANALYSIS OF LANDMARK PHASE III TRIALS AND VALIDATION IN ROUTINE CLINICAL PRACTICE 58
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 55
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 55
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 54
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 52
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 51
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 51
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 50
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 50
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome 49
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 49
Where are we with treatment options after first line in small cell lung cancer?-Report of two opposite cases treated with CAPTEM regimen and possible perspectives 47
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 42
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study 41
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 40
Into the storms: Organising oncological home care services during natural disasters and global pandemics 40
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 38
SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY 33
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab 32
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 25
Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience 19
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma 18
Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors 17
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 13
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study 11
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma 10
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers 5
Totale 6.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.484
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.484
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202229 0 0 0 0 0 2 1 1 13 1 6 5
2022/202371 5 3 4 10 0 11 0 2 18 7 10 1
2023/2024254 16 3 13 19 18 27 2 13 1 71 25 46
2024/20251.356 151 76 42 12 39 50 200 67 274 96 115 234
2025/20264.568 213 343 198 478 337 303 849 436 469 494 248 200
2026/2027663 304 279 80 0 0 0 0 0 0 0 0 0
Totale 6.986